Report Publication Announcement • Feb 9, 2015
Report Publication Announcement
Open in ViewerOpens in native device viewer
Bagneux (France) - Genomic Vision (FR0011799907 – GV / PEA-PME eligible), a molecular diagnostics company specialized in the development of diagnostic tests for genetic diseases and cancers based on molecular combing, today publishes its financial agenda for 2015. This preliminary agenda may be modified.
| Event | Date |
|---|---|
| 2014 Full-Year Results | Wednesday, March 18, 2015 |
| Q1 2015 Revenue | Wednesday, May 6, 2015 |
| Shareholders' Meeting | Thursday, June 18, 2015 |
| 2015 Half-Year Results | Friday, July 31, 2015 |
| Q3 2015 Revenue | Thursday, October 22, 2015 |
●●●
Founded in 2004, Genomic Vision is a molecular diagnostics company specialized in the development of diagnostic tests for genetic diseases and cancers based on molecular combing. Using this innovative technology that allows the direct visualization of individual DNA molecules, Genomic Vision detects quantitative and qualitative variations in the genome that are at the origin of numerous serious pathologies. The Company is developing a solid portfolio of tests that notably target breast cancer and cancer of the colon. Since 2013, the Company has marketed the CombHeliX FSHD test for identifying a myopathy that is difficult to detect, Facio-scapulo-humeral dystrophy (FSHD), in the United States thanks to a strategic alliance with Quest Diagnostics, the American leader in diagnostic laboratory tests, and in France. Genomic Vision has been listed on Compartment C of Euronext Paris since April 2014.
DNA molecular combing technology considerably improves the structural and functional analysis of DNA molecules. DNA fibers are stretched out on glass slides, as if "combed", and uniformly aligned over the whole surface. It is then possible to identify genetic anomalies by locating genes or specific sequences in a patient's genome using genetic markers, an approach developed by Genomic Vision and patented under the name Genomic Morse Code. This exploration of the entire genome at high resolution via a simple analysis enables the direct visualization of genetic anomalies that are undetectable by other technologies.
For further information, please go to www.genomicvision.com
Genomic Vision
Aaron Bensimon Co-founder, Chairman & CEO Tel.: +33 1 49 08 07 50 [email protected]
NewCap
Investor Relations / Strategic Communications Dušan Orešanský / Emmanuel Huynh Tel.: +33 1 44 71 94 92 [email protected]
Member of CAC® Mid & Small, CAC® All-Tradable and EnterNext© PEA-PME 150 indexes
This press release contains certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the prospectus on which the French Financial Market Authority (AMF) granted its visa n° 14-087 on March 19, 2014 and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.
This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for GENOMIC VISION shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.